
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with ...
- Top-line data for SPIRIT 2 expected in first quarter of 2020 - Company on track to announce top-line results from SPIRIT 1 in second quarter of 2020 BRISBANE, Calif., and BASEL, Switzerland, Aug. 20, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV …